α Glucosidase inhibitors v placebo in type 2 diabetes*
| Comparisons | Number of comparisons (n) | Outcomes | Weighted mean difference (95% CI) | ||
|---|---|---|---|---|---|
| Acarbose v placebo | 28 (2831) | Change in glycated haemoglobin (%) | −0.8 (−0.9 to −0.6) | ||
| Miglitol v placebo | 7 (1088) | −0.7 (−0.9 to −0.4) | |||
| Voglibose v placebo | 1 (238) | −0.5 (−0.6 to −0.3) | |||
| Acarbose v placebo | 28 (2838) | Change in fasting blood glucose (mmol/l [mg/dl]) | −1.1 (−1.4 to −0.8) [−19.8 (−14.4 to −25.2)] | ||
| Miglitol v placebo | 2 (398) | −0.5 (−0.9 to −0.2) [−9.0 (−3.6 to −16.2)] | |||
| Voglibose v placebo | 1 (234) | −0.6 (−1.0 to −0.2) [−10.8 (−3.6 to −18)] | |||
| Event rates | RRI (CI) | NNH (CI) | |||
|---|---|---|---|---|---|
| *Abbreviations defined in glossary; RRI, NNH, and CI calculated from data in article using a random effects model. Most studies were 24 weeks in duration. | |||||
| Acarbose v placebo | 4 (1442) | Gastrointestinal adverse effects | 59% v 34% | 86% (60 to 110) | 4 (3 to 5) |